{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039068","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.166880+00:00","generated_at":"2026-06-12T03:45:26.359280+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight Q2 revenue $20.8M (+83% YoY); raises FY2023 guidance; pays off $40M debt","bullets":["Q2 revenue $20.8M (+83% YoY); net loss $(13.8)M vs $(16.7)M last year.","Raised FY2023 revenue guidance to $81-86M (prior $79-84M); gross margin 58-60%.","LAL procedure volumes 12,622 (+134% YoY); LDD installed base 523 (+78% YoY).","Paid off $40M debt in Q2 and early Q3, eliminating ~$5.6M annual interest expense.","Raised ~$31.3M net from ATM in Q2 and early Q3 to fund debt repayment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039068","json":"https://secwatch.observer/filing/0000950170-23-039068.json","markdown":"https://secwatch.observer/filing/0000950170-23-039068.md","text":"https://secwatch.observer/filing/0000950170-23-039068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023039068/0000950170-23-039068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023039068/rxst-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:45:26.359280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d9f41bda0aaa35ee0e36e6cb8a0115eb1b3a55e3","claim":"RxSight, Inc. reported three and six months ended June 30, 2023 results: revenue $20.8 million, net income $(13.8) million, EPS $(0.40) per basic and diluted share. Guidance raised.","evidence_excerpt":"following cataract surgery, today reported financial results for the three and six months ended June 30, 2023. Key Quarterly Highlights • Reported second quarter 2023 revenue of $20.8 million, an increase of 83% compared to the second quarter of 2022, reflecting: • The sale of 67 Light Delivery Devices (LDDTMs), representing a 37% increase in unit sales compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023039068/0000950170-23-039068-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and six months ended June 30, 2023"},{"label":"Revenue","value":"$20.8 million"},{"label":"Net income","value":"$(13.8) million"},{"label":"EPS","value":"$(0.40) per basic and diluted share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}